Listed

Sunshine Biopharma Inc.: Form 10-K for the period ended Dec 31, 2012

Filed with the SEC on Mar 15, 2013 and accepted by EDGAR at Mar 15, 2013, 13:51 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2012-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2012-01-01 to 2012-12-31$1.8kus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2012-01-01 to 2012-12-31−$706.7kus-gaap:OperatingIncomeLoss
Interest expense12 months2012-01-01 to 2012-12-31$1.3kus-gaap:InterestExpense
Net income12 months2012-01-01 to 2012-12-31−$708.0kus-gaap:NetIncomeLoss
Basic EPS12 months2012-01-01 to 2012-12-31−$0.01us-gaap:EarningsPerShareBasic
Operating cash flow12 months2012-01-01 to 2012-12-31−$393.1kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2012-12-31$132.6kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2012-12-31$134.8kus-gaap:AssetsCurrent
Total assetsAt period end2012-12-31$134.8kus-gaap:Assets
Total liabilitiesAt period end2012-12-31$64.4kus-gaap:Liabilities
Shareholders' equityAt period end2012-12-31$70.4kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001354488-13-001224. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.